 |
72 Diseases |  |
11 Trials |
|
11 Trials |  |
447 News |  |
| «12345» |
- || Clinical, Observational data, Journal: Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study. (Pubmed Central) - Mar 4, 2020
This is the second study that compared a 0.25 mg dose of palonosetron with first-generation setron in triplet antiemetic prophylaxis in cancer patients receiving HEC. We could not find meaningful statistical differences between two arms, regarding CR rate on acute and delayed CINV.
- palonosetron intravenous / Generic mfg.
Comparative study between the clinical effect of Palonosetron and Granisetron as antiemetic therapy for patients receiving highly emetogenic chemotherapy regimens (Exhibition area) - Mar 4, 2020 - Abstract #ESMOBC2020ESMO_BC_418;
- || Clinical, Journal, CINV: A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide. (Pubmed Central) - Mar 3, 2020
Olanzapine 10 mg combined with ondansetron and dexamethasone was more effective than a placebo in preventing CINV resulting from doxorubicin plus cyclophosphamide in early-stage breast cancer patients, especially in the first 24 hours after chemotherapy administration. The short duration of olanzapine was safe and well tolerated.
- || Decadron (dexamethasone) / Merck (MSD), palonosetron intravenous / Generic mfg.
Clinical, Journal: Pediatric ambulatory anesthesia: an update. (Pubmed Central) - Mar 2, 2020
Furthermore, postdischarge nonsteroidal anti-inflammatory agents as well as other pain management strategies should replace oral opioids to prevent respiratory arrests in those who are ultra-rapid CYP2D6 metabolizers. Finally, discharge criteria are evolving and physiological-based criteria should replace time-based, reducing the risk of readmission.
- | Retrospective data, Journal: Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review. (Pubmed Central) - Mar 2, 2020
No TEAEs occurred within 60 minutes after start of HTX-019 administration. HTX-019 administered by 2-minute injection has a tolerable safety profile in patients with cancer, representing a viable method of HTX-019 administration for CINV prevention.
- Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, netupitant (Ro 67-3189) / Helsinn, Otsuka, palonosetron intravenous / Generic mfg.
[VIRTUAL] Antiemetic prophylaxis with NEPA: Final results of the German AKYPRO study. (Poster Board 383) - Feb 27, 2020 - Abstract #ASCO2020ASCO_770;
Over 80% of pts reported that their daily live was not influenced by emesis while nausea was more difficult to control. Effectiveness was high and patients and physicians estimate was comparable.
- carboplatin / Generic mfg., palonosetron intravenous / Generic mfg.
Improving Chemotherapy induced Nausea and Vomiting for Carboplatin AUC ≥ 4: Assessing CINV Guideline Compliance (Henry B. Gonzalez Convention Center - Tower View Registration) - Feb 17, 2020 - Abstract #ONS2020ONS_496;
In the case of CINV, while emesis control has been improved with the myriad of medications available, nausea remains, for many, a difficult to control symptom. Compliance with evidence based guidelines may offer the best strategies for improving patient related outcomes.
- || Clinical, PK/PD data, Journal: Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial. (Pubmed Central) - Jan 25, 2020
This study showed that aprepitant in combination with palonosetron and dexamethasone was safe and effectively controlled CINV in sarcoma patients receiving ifosfamide and doxorubicin chemotherapy. Aprepitant may have a low potential to affect the pharmacokinetics of chemotherapeutic agents metabolized by CYP3A4.
- ||| palonosetron intravenous / Generic mfg.
Clinical, FDA event: Thank you. I did ask and “trial protocol” said I had to suffer first and then they would give me aloxi (?sp) next time. And now w fda approval I have options. (Twitter) - Dec 30, 2019
- || ondansetron / Generic mfg., palonosetron intravenous / Generic mfg.
Clinical, Journal, CINV: Palonosetron is a Better Choice Compared With Ondansetron for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in a Resource-limited Pediatric Oncology Center: Results From a Randomized Control Trial. (Pubmed Central) - Dec 23, 2019
Complete protection rates, defined as no nausea and vomiting in children above 6 years of age, in acute, delayed, and overall phases were 84%, 81%, and 73%, respectively, for PG versus 79%, 67%, and 60%, respectively, for OG (P=0.44, 0.06 and 0.10, respectively). Overall, the efficacy and safety of PG in the prevention of chemotherapy-induced nausea and vomiting was comparable with OG, but PG was a more cost-effective and suitable choice for busy centers in resource-limited countries.
- | palonosetron intravenous / Generic mfg.
Review, Journal: Cannabis and cannabinoids. (Pubmed Central) - Dec 22, 2019
Overall, the efficacy and safety of PG in the prevention of chemotherapy-induced nausea and vomiting was comparable with OG, but PG was a more cost-effective and suitable choice for busy centers in resource-limited countries. No abstract available
- | Retrospective data, Review, Journal: Drugs for preventing post-operative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: Network meta-analysis of randomized clinical trials and trial sequential analysis. (Pubmed Central) - Dec 19, 2019
Dexamethasone and ondansetron have the best evidence as stand-alone options and the combination is preferred in high-risk category. Caution should be exercised while interpreting the evidence as the estimates might change with head-to-head clinical trial data.
- | palonosetron intravenous / generics
Retrospective data, Review, Journal, CINV: Do we still need to study palonosetron for chemotherapy-induced nausea and vomiting? A cumulative meta-analysis. (Pubmed Central) - Nov 29, 2019
Caution should be exercised while interpreting the evidence as the estimates might change with head-to-head clinical trial data. Considering the vast amount of resources needed to conduct RCTs, resources should be dedicated to other prophylactic treatments/settings which have not been as well explored.
- | olanzapine / Generic Mfg.
Retrospective data, Journal: Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study. (Pubmed Central) - Nov 22, 2019
Additionally, treatment-related adverse events were well tolerated in both the groups. These findings suggest that the antiemetic efficacy of the four-drug combination is superior to that of the standard three-drug combination.
- || Decadron (dexamethasone) / Merck (MSD), ondansetron / Generic mfg., palonosetron intravenous / Generic mfg.
Clinical, Journal: A unique schedule of palonosetron, ondansetron, and dexamethasone for the prevention of delayed nausea and vomiting in patients receiving myeloablative chemotherapy. (Pubmed Central) - Nov 21, 2019
By day 6 however, nausea alone had a statistically significant impact on quality of life. In our study, PAL controlled nausea severity and sustained quality of life, but further strategies are needed to control delayed CINV associated with the auto-SCT process.
- | dexamethasone / generics, palonosetron intravenous / generics
Clinical, Journal, Combination therapy: Multi-Center Joint Study on the Survey of Antiemetic Therapy for the Prevention of Nausea and Vomiting in Combination Therapy with a Mild Emetic Antineoplastic Drug (Pubmed Central) - Nov 10, 2019
Gemcitabine and nab-paclitaxel were the most commonly used with a total of 64 patients receiving a combination of these mildly emetogenic agents. Poor performance status was associated with failure to achieve total control(TC)of nausea and vomiting(p=0.0304), while habitual alcohol consumption was associated with TC of nausea and vomiting(p=0.0331).
- | dexamethasone / generics, cisplatin / generics, palonosetron intravenous / generics
Journal, HEOR: Cost-utility analysis of palonosetron in the antiemetic regimen for cisplatin-containing highly emetogenic chemotherapy in Japan. (Pubmed Central) - Nov 6, 2019
If willingness-to-pay is taken as 5,000,000 JPY/QALY (44,575 USD/QALY), the antiemetic regimen using PALO for cisplatin-containing HEC was not cost-effective at this time. The cost of drugs, with the arrival of inexpensive generic drugs, will make a major contribution to its cost-effectiveness.
- | dexamethasone / generics, palonosetron intravenous / generics
Observational data, Retrospective data, Journal: Patient-Related Risk Factors for Nausea and Vomiting with Standard Antiemetics in Patients with Breast Cancer Receiving Anthracycline-Based Chemotherapy: A Retrospective Observational Study. (Pubmed Central) - Oct 25, 2019
The cost of drugs, with the arrival of inexpensive generic drugs, will make a major contribution to its cost-effectiveness. The present findings suggest that, among patients with breast cancer receiving anthracycline and treated with aprepitant, palonosetron, and dexamethasone, patients younger than 55 years and having a body mass index <27.5 kg/m are high-risk populations for chemotherapy-induced nausea and vomiting, whereas those with a history of habitual alcohol consumption is a low-risk one.
- ondansetron / generics, cisplatin / generics, palonosetron intravenous / generics
Effects of 5-HT3A Antiemetic Drugs on Cisplatin-Induced Nephrotoxicity () - Oct 23, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_5237;
Increased risk of cisplatin-induced tubular toxicity in this scenario is likely further offset by the lower risk of pre-renal AKI from vomiting and anorexia, incited by cisplatin. Effects of the individual 5-HT3 RA on renal outcomes are the subject of active investigation.
- | ondansetron / generics, palonosetron intravenous / generics
Clinical, Review, Journal: Evolution of antiemetic studies for radiation-induced nausea and vomiting within an outpatient palliative radiotherapy clinic. (Pubmed Central) - Oct 17, 2019
Effects of the individual 5-HT3 RA on renal outcomes are the subject of active investigation. These studies provide a framework for future research and could potentially inform changes to future guidelines to include the use of these novel regimens and techniques.
- ondansetron / generics, palonosetron intravenous / generics
The reliability of skin testing in suspected perioperative Ondansetron allergy. () - Oct 14, 2019 - Abstract #BSACI2019BSACI_4;
These apparently positive results should not deter clinicians from carrying out oral challenge with Ondansetron. In particular, as labelling patients with Ondansetron allergy will deprive them of very effective antiemetic and likely result in avoidance of other 5HT3 inhibitors such as Granisetron and Palonosetron.
- | Clinical, Journal, Real-world evidence, CINV: Real-world efficacy: intravenous palonosetron three-drug regimen for chemotherapy-induced nausea and vomiting with highly emetogenic chemotherapy. (Pubmed Central) - Sep 26, 2019
In particular, as labelling patients with Ondansetron allergy will deprive them of very effective antiemetic and likely result in avoidance of other 5HT3 inhibitors such as Granisetron and Palonosetron. Even within a recommended three-drug antiemetic regimen, palonosetron may provide suboptimal chemotherapy-induced nausea and vomiting control with HEC in real-world settings.
- | cisplatin / Generic mfg.
Enrollment open, Trial primary completion date: Cisplatin Disposition and Kidney Injury (clinicaltrials.gov) - Sep 25, 2019
P=N/A, N=72, Recruiting, Sponsor: University of Colorado, Denver
Even within a recommended three-drug antiemetic regimen, palonosetron may provide suboptimal chemotherapy-induced nausea and vomiting control with HEC in real-world settings. Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2022 --> Sep 2022
- Efficacy of intravenous (IV) NEPA and oral NEPA, fixed NK15-HT3 receptor antagonist (RA) combination agents, for prevention of chemotherapy-induced nausea and vomiting (CINV) following anthracycline-cyclophosphamide (AC)-based chemotherapy (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_561;
Two studies were completed in patients receiving cisplatin (Phase 3) or AC (Phase 3b) to assess the safety of IV NEPA, with specific attention paid to injection-site/hypersensitivity reactions as such events have occurred with other NK1 RAs, particularly in the AC setting... Both IV and oral formulations of NEPA in combination with DEX represent guideline-compliant single-dose antiemetic agents that are highly effective over 5 days in patients receiving AC-based chemotherapy.
- | palonosetron intravenous / generics
Clinical, Journal, Combination therapy: Aprepitant in combination with palonosetron for the prevention of postoperative nausea and vomiting in female patients using intravenous patient-controlled analgesia. (Pubmed Central) - Sep 22, 2019
There was no difference between the groups in severity of nausea during the first 24 h after surgery (P > 0.05). : Aprepitant combined with palonosetron did not reduce the incidence of PONV as compared to palonosetron alone within 24 h of surgery in women receiving fentanyl-based IV-PCA.
- | amisulpride / generics, palonosetron intravenous / generics
Review, Journal: Updates in the Management of Postoperative Nausea and Vomiting. (Pubmed Central) - Sep 20, 2019
: Aprepitant combined with palonosetron did not reduce the incidence of PONV as compared to palonosetron alone within 24 h of surgery in women receiving fentanyl-based IV-PCA. No abstract available
- Varubi (rolapitant oral) / TerSera Therap, GSK, Imperan (metoclopramide) / Generic Mfg.
Supportive care to control nausea and dizziness in malignant tumours: A systematic review (Exhibition area) - Sep 17, 2019 - Abstract #ESMOAsia2019ESMO_ASIA_779;
The neurokinin-1 receptor rolapitant is a possible alternative [5].Legal entity responsible for the study: The first author and the last author. Funding: Has not received any funding.
- palonosetron intravenous / generics
Economic and safety evaluation of 5-HT3 recepter antagonist conversion from palonosetron to granisetron in highly and moderately emetogenic chemotherapy: A prospective study (Exhibition area) - Sep 17, 2019 - Abstract #ESMOAsia2019ESMO_ASIA_754;
When patients receiving HEC or MEC with PALO were assessed as CR, we should consider conversion of 5HT3RA.Legal entity responsible for the study: Asahikawa medical University. Funding: Has not received any funding.
- dexamethasone / generics, palonosetron intravenous / generics
Effectiveness of first-generation 5HT3 receptor antagonist plus dexamethasone plus aprepitant in controlling delayed chemotherapy-induced nausea and vomiting in patients with colorectal cancer: A propensity score-matched analysis (Exhibition area) - Sep 17, 2019 - Abstract #ESMOAsia2019ESMO_ASIA_752;
Thus, patients with CRC receiving L-OHP-based chemotherapy should be treated with three antiemetics, including APR.Legal entity responsible for the study: The authors. Funding: Has not received any funding.
- Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, netupitant (Ro 67-3189) / Helsinn, Otsuka
Patient-reported outcome data during real-world use of NEPA for prevention of chemotherapy-induced nausea and vomiting in high-risk platin-receiving patients: A prospective multicenter trial (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_1767;
Despite the reported MEC classification of oxaliplatin in contrast to the HEC classification of cis- and carboplatin, nausea was more difficult to control in oxaliplatin-receiving patients. Legal entity responsible for the study: Riemser Pharma.
- Akynzeo IV (fosnetupitant/palonosetron) / Helsinn, netupitant (Ro 67-3189) / Helsinn, Otsuka, Varubi IV (rolapitant IV) / TerSera Therap, GSK
Efficacy of intravenous (IV) NEPA, a fixed NK1/5-HT3 receptor antagonist (RA) combination, for prevention of CINV following cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy (CT) (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_1765;
P3b
Clinical trial identification: NCT03403712. Legal entity responsible for the study: Helsinn Healthcare.
- olanzapine / Generic Mfg.
A phase III trial evaluating olanzapine 5 mg for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin: J-FORCE study (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_1764;
Sleepiness during daytime due to OLZ 5 mg seems to be tolerable and addition of OLZ 5mg to the standard antiemetic therapy may reduce appetite loss. Legal entity responsible for the study: Masakazu Abe.
- | dexamethasone / generics, irinotecan / generics, palonosetron intravenous / generics
Clinical, Journal: Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens. (Pubmed Central) - Sep 11, 2019
Legal entity responsible for the study: Masakazu Abe. The control for nausea in MEC was insufficient even with palonosetron and aprepitant, and we should pay attention to risk factors for preventing nausea.
- | palonosetron intravenous / generics
Retrospective data, Journal: Anti-Tumor Potential of a 5-HT3 Receptor Antagonist as a Novel Autophagy Inducer in Lung Cancer: A Retrospective Clinical Study with In Vitro Confirmation. (Pubmed Central) - Sep 6, 2019
Our in vitro experiments also showed that palonosetron and ramosetron inhibited cell proliferation and colony formation and reduced migration, which was associated with autophagic cell death via the extracellular signal-regulated kinase (ERK) pathway. Palonosetron and ramosetron may have anti-tumor potential against lung cancer cells, suggesting the need to consider these drugs as first-choice antiemetics in patients undergoing lung cancer surgery.
- | Imperan (metoclopramide) / Generic Mfg.
Clinical, Journal: Efficacy of Palonosetron as Antiemetic Prophylaxis for Post Operative Patients. (Pubmed Central) - Aug 9, 2019
Nausea was found 3(8.8%) in group A, 8(23.5%) in group B and 6(17.6%) in group C. Vomiting was found 3(8.8%) in group A, 10(29.4%) in group B and 7(20.6%) in group C. Vomiting was significantly higher in group B compare with group A. For group B rescue anti-emetic injection motilon (metoclopramide hydrochloride) 5mg IV slowly was given. Palonosetron is effective prophylaxis against post operative nausea and vomiting.
- | Imperan (metoclopramide) / Generic Mfg.
Journal: Comparison of ondansetron, tropisetron, and palonosetron for the prevention of postoperative nausea and vomiting after middle ear surgery. (Pubmed Central) - Aug 7, 2019
...During skin closure, 0.075 mg palonosetron, 5 mg tropisetron, and 8 mg ondansetron were administered intravenously to the palonosetron, tropisetron, and ondansetron groups, respectively...Diclofenac sodium (100 mg IM) was administered to patients experiencing pain and metoclopramide chloride (10 mg IM) was administered to patients with nausea or vomiting...(Curr Ther Res Clin Exp. 2019; 80:XXXXXX).
- | dexamethasone / generics, cyclophosphamide intravenous / generics, palonosetron intravenous / generics
Clinical, P3 data, Journal: Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1 to 3 With Combined Neurokinin-1 Receptor Antagonist and Palonosetron in High-Emetogenic Chemotherapy. (Pubmed Central) - Aug 3, 2019
As an indication of quality of life, global health status was similar in both arms. Conclusion Antiemetic DEX administration on days 2 and 3 can be spared when combined with NK-RA and Palo in HEC.
- | Eladur (bupivacaine) / Impax
Clinical, Journal: Comparison of IV granisetron and IV palonosetron on hemodynamics and sensory and motor block after spinal anesthesia with hyperbaric bupivacaine in patients undergoing abdominal hysterectomy. (Pubmed Central) - Jul 16, 2019
The incidence of nausea and vomiting was significantly lower in group G and P. Intravenous administration of granisetron and palonosetron before intrathecal bupivacaine does not attenuate the hemodynamic changes in patients undergoing abdominal hysterectomy. Further, both 5-HT3 receptors antagonists do not have clinically significant effects on the spinal blockade produced by hyperbaric bupivacaine.
- | ondansetron / generics, palonosetron intravenous / generics
Clinical, Journal: A randomized study to compare palonosetron with ondansetron for prevention of postoperative nausea and vomiting following middle ear surgeries. (Pubmed Central) - Jul 16, 2019
QTc interval prolongation, a known side effect of ondansetron was not found in palonosetron group intraoperatively. Palonosetron was found to be superior to ondansetron up to 12 hours after the surgery with no significant effect on QTc interval.
- | dexamethasone / generics, palonosetron intravenous / generics
Clinical, Journal: Hydration requirements in patients receiving highly emetogenic chemotherapy. (Pubmed Central) - Jun 30, 2019
Palonosetron was found to be superior to ondansetron up to 12 hours after the surgery with no significant effect on QTc interval. GERSC within a three-drug antiemetic regimen may reduce unscheduled hydration requirements with MEC or HEC.
- | dexamethasone / generics, cisplatin / generics, palonosetron intravenous / generics
Clinical, P3 data, Journal: Phase III Randomized Trial of Palonosetron and Dexamethasone With or Without Aprepitant to Prevent Nausea and Vomiting Induced by Full-dose Single-day Cisplatin-based Chemotherapy in Lung Cancer. (Pubmed Central) - Jun 28, 2019
GERSC within a three-drug antiemetic regimen may reduce unscheduled hydration requirements with MEC or HEC. Aprepitant plus palonosetron and dexamethasone proved to be effective and well-tolerated in preventing chemotherapy-induced nausea and vomiting after administration of full-dose single-day cisplatin-based combination chemotherapy.
- | Clinical, Journal: Short-course olanzapine to prevent delayed emesis following carboplatin/paclitaxel for gynecologic cancer: a randomised study. (Pubmed Central) - Jun 23, 2019
FLIE scores as well as mean satisfaction scores were similar across arms. In this exploratory study with a small sample size, we did not find any clue about better control of delayed emesis with either olanzapine regimen in gynecologic cancer patients treated with carboplatin/paclitaxel and receiving the same prophylaxis for acute emesis.
- | dexamethasone / generics, ondansetron / generics, palonosetron intravenous / generics
Clinical, Journal: Comparison of Palonosetron and Dexamethasone with Ondansetron and Dexamethasone to Prevent Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Cholecystectomy. (Pubmed Central) - Jun 16, 2019
Headache was present in three patients in Group I and two patients of Group II. The palonosetron with dexamethasone is comparable to ondansetron with dexamethasone in the prevention of PONV in patients undergoing LC.
- | Emend intravenous (fosaprepitant) / Merck (MSD), Novartis
Clinical, Journal: Low-dose dexamethasone with fosaprepitant and palonosetron to prevent cisplatin-induced nausea and vomiting in head and neck cancer patients. (Pubmed Central) - Jun 7, 2019
The palonosetron with dexamethasone is comparable to ondansetron with dexamethasone in the prevention of PONV in patients undergoing LC. The efficacy of low-dose dexamethasone with fosaprepitant and palonosetron was not inferior to that of the standard dose dexamethasone in the highly emetogenic cisplatin-based treatment for head and neck cancer patients.
- | palonosetron intravenous / generics
Journal: Palonosetron on Days 1 and 5 Versus Granisetron Daily (Days 1-5) in Germ Cell Tumour Therapy. (Pubmed Central) - Jun 6, 2019
The efficacy of low-dose dexamethasone with fosaprepitant and palonosetron was not inferior to that of the standard dose dexamethasone in the highly emetogenic cisplatin-based treatment for head and neck cancer patients. The Pal method may be the standard method in BEP.
- | dexamethasone / generics, carboplatin / generics, palonosetron intravenous / generics
Clinical, P2 data, Journal: Efficacy of palonosetron plus dexamethasone in preventing chemotherapy-induced nausea and emesis in patients receiving carboplatin-based chemotherapy for gynecologic cancers: a phase II study by the West Japan Gynecologic Oncology Group (WJGOG 131). (Pubmed Central) - May 29, 2019
The Pal method may be the standard method in BEP. While palonosetron effectively controls acute CINV, additional antiemetic management is warranted in the delayed phase after carboplatin-based chemotherapy in gynecologic cancer patients (Trial registry at UMIN Clinical Trials Registry, UMIN000012806).
- | ondansetron / generics, palonosetron intravenous / generics
Clinical, Journal: Use of palonosetron and ondansetron in the prophylaxis of postoperative nausea and vomiting in women 60 years of age or older undergoing laparoscopic cholecystectomy: A randomised double-blind study. (Pubmed Central) - May 29, 2019
While palonosetron effectively controls acute CINV, additional antiemetic management is warranted in the delayed phase after carboplatin-based chemotherapy in gynecologic cancer patients (Trial registry at UMIN Clinical Trials Registry, UMIN000012806). No abstract available
- | Cinvanti (aprepitant IV) / Heron Therap
Clinical, Journal: Crossover safety study of aprepitant: 2-min injection vs 30-min infusion in cancer patients receiving emetogenic chemotherapy. (Pubmed Central) - May 25, 2019
No TEAEs were considered related to HTX-019. Short injection of HTX-019 has a tolerable safety profile in patients with cancer, and represents an alternative method of HTX-019 administration for CINV prevention.
- | palonosetron intravenous / generics
Journal: The effect of palonosetron on rocuronium-induced withdrawal movement (Pubmed Central) - May 11, 2019
Pretreatment of palonosetron with venous occlusion may attenuate rocuronium-induced withdrawal movement as effective as the use of lidocaine. It suggested that peripheral action of palonosetron was effective to reduce rocuronium-induced withdrawal movement.
- | fosaprepitant / Generic mfg.
Trial completion date, Trial primary completion date: A221602: Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy (clinicaltrials.gov) - May 2, 2019
P3, N=690, Recruiting, Sponsor: Alliance for Clinical Trials in Oncology
It suggested that peripheral action of palonosetron was effective to reduce rocuronium-induced withdrawal movement. Trial completion date: Mar 2020 --> Aug 2023 | Trial primary completion date: May 2019 --> May 2023